Home > Insider Trading > Filing (0001209191-16-111235)

Filing Details

Accession Number:: 0001209191-16-111235
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-03-31 16:59:07
Reporting Period:: 2016-03-29

Filing Date:: 2016-03-31
Accepted Time:: 2016-03-31 16:59:07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631650	Aimmune Therapeutics Inc.	AIMT	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1253886	G Patrick Enright	800 El Camino Real, Suite 220 Menlo Park CA 94025	No	No	Yes	No
1431159	Juliet Bakker Tammenoms	800 El Camino Real, Suite 220 Menlo Park CA 94025	No	No	Yes	No
1527510	Longitude Venture Partners Ii, L.p.	800 El Camino Real, Suite 220 Menlo Park CA 94025	No	No	Yes	No
1647491	Longitude Capital Partners Ii, Llc	800 El Camino Real, Suite 220 Menlo Park CA 94025	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2016-03-29	33,064	$13.50	7,467,694	No	4	P	Indirect	By Longitude Venture Partners II, L.P.
Common Stock, $0.0001 Par Value	Acquisiton	2016-03-29	45,440	$14.15	7,513,134	No	4	P	Indirect	By Longitude Venture Partners II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Longitude Venture Partners II, L.P.
No	4	P	Indirect	By Longitude Venture Partners II, L.P.

Footnotes

Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $12.90 to $13.89. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
This report is filed jointly by Longitude Capital Partners II, LLC ("Longitude Capital II"), Longitude Venture Partners II, L.P. ("Longitude Venture II"), Patrick G. Enright ("Mr. Enright") and Juliet Tammenoms Bakker ("Ms. Bakker"), all of whom share beneficial ownership of more than 10% of the capital stock of the Issuer. Longitude Capital II as general partner of Longitude Venture II maybe deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Mr. Enright and Ms. Bakker are each managing members of Longitude Capital II and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Reporting Persons. Each of Longitude Capital II, Mr. Enright and Ms. Bakker disclaims beneficial ownership of such shares except to the extent of its, his or her pecuniary interest therein.
Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $13.90 to $14.29. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.